Why is Bliss GVS Pharma falling/rising?

As of 13-Nov, Bliss GVS Pharma Ltd is experiencing a price increase, currently at 167.25, reflecting a rise of 6.95 or 4.34%. The stock has shown strong performance recently, gaining 30.56% over the last four days and outperforming its sector by 4.13% today. It has also consistently traded above its moving averages across various time frames, indicating positive momentum. Over the past year, the stock has generated a remarkable return of 42.64%, significantly outpacing the broader market's return of 8.17%. The company's low debt-to-equity ratio and fair valuation, alongside a PEG ratio of 0.9, suggest that the stock is positioned well for continued growth, despite trading at a premium compared to its peers.
In the broader market context, Bliss GVS Pharma's short-term performance has been notably strong, with a weekly return of 10.11% compared to the Sensex's 1.40%. This outperformance highlights the stock's resilience and attractiveness to investors, especially given its substantial gains over the past three years at 128.64%, compared to the Sensex's 36.71%. However, it is worth noting that there has been a decline in investor participation, with delivery volume dropping significantly, which could indicate a potential concern for sustained momentum. Nonetheless, the liquidity of the stock remains adequate for trading, suggesting that it continues to attract interest despite the recent drop in delivery volume.